Brain Advance Access originally published online on April 17, 2008
Brain 2008 131(5):1228-1240; doi:10.1093/brain/awn053
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Interrelation of inflammation and APP in sIBM: IL-1β induces accumulation of β-amyloid in skeletal muscle
1Neuromuscular Diseases Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland, USA, 2Department of Neurology and Department of Experimental and Clinical Neuroimmunology, 3Department of Neuropathology, University of Göttingen, Germany and 4Neuromuscular Division, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA
Correspondence to: Dr Jens Schmidt, Department of Neurology and Department of Experimental and Clinical Neuroimmunology, University of Göttingen, Waldweg 33, 37073 Göttingen, Germany, or Dr Marinos Dalakas, Neuromuscular Division, Thomas Jefferson University, 900 Walnut Street, Suite 200, Philadelphia, PA 19107, USA E-mail: j.schmidt{at}gmx.org or marinos.dalakas{at}jefferson.edu
Distinct interrelationships between inflammation and β-amyloid-associated degeneration, the two major hallmarks of the skeletal muscle pathology in sporadic inclusion body myositis (sIBM), have remained elusive. Expression of markers relevant for these pathomechanisms were analysed in biopsies of sIBM, polymyositis (PM), dermatomyositis (DM), dystrophic and non-myopathic muscle as controls, and cultured human myotubes. By quantitative PCR, a higher upregulation was noted for the mRNA-expression of CXCL-9, CCL-3, CCL-4, IFN-
, TNF-
and IL-1β in sIBM muscle compared to PM, DM and controls. All inflammatory myopathies displayed overexpression of degeneration-associated markers, yet only in sIBM, expression of the mRNA of amyloid precursor protein (APP) significantly and consistently correlated with inflammation in the muscle and mRNA-levels of chemokines and IFN-
. Only in sIBM, immunohistochemical analysis revealed that inflammatory mediators including IL-1β co-localized to β-amyloid depositions within myofibres. In human myotubes, exposure to IL-1β caused upregulation of APP with subsequent intracellular aggregation of β-amyloid. Our data suggest that, in sIBM muscle, production of high amounts of pro-inflammatory mediators specifically induces β-amyloid-associated degeneration. The observations may help to design targeted treatment strategies for chronic inflammatory disorders of the skeletal muscle.
Key Words: muscle inflammation; protein aggregation; autoimmunity; β-amyloid; chemokines and cytokines
Abbreviations:
APP, amyloid precursor protein; BACE-1, β-site of APP cleaving enzyme 1; DM, dermatomyositis; IFN-
, interferon-
; IL-1β, interleukin-1β; IL-6, interleukin-6; MHC class-I, major histocompatibility complex class I; NCAM, neural cell adhesion molecule; PM, polymyositis; sIBM, sporadic inclusion body myositis; TGF-β, transforming growth factor-β; TNF-
, tumour necrosis factor-
Received October 27, 2007. Revised February 12, 2008. Accepted February 26, 2008.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. C. Dalakas, G. Rakocevic, J. Schmidt, M. Salajegheh, B. McElroy, M. O. Harris-Love, J. A. Shrader, E. W. Levy, J. Dambrosia, R. L. Kampen, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis Brain, June 1, 2009; 132(6): 1536 - 1544. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kitazawa, V. Vasilevko, D. H. Cribbs, and F. M. LaFerla Immunization with Amyloid-{beta} Attenuates Inclusion Body Myositis-Like Myopathology and Motor Impairment in a Transgenic Mouse Model J. Neurosci., May 13, 2009; 29(19): 6132 - 6141. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Greenberg Comment on 'Interrelation of inflammation and APP in sIBM: IL-1{beta} induces accumulation of {beta}-amyloid in skeletal muscle' Brain, April 1, 2009; 132(4): e106 - e106. [Full Text] [PDF] |
||||
![]() |
J. Schmidt and M. C. Dalakas Inflammation interrelates to APP in sIBM: IL-1{beta} induces accumulation of {beta}-amyloid Brain, April 1, 2009; 132(4): e107 - e107. [Full Text] [PDF] |
||||
![]() |
M. C. Dalakas Review: Therapeutic advances and future prospects in immune-mediated inflammatory myopathies Therapeutic Advances in Neurological Disorders, November 1, 2008; 1(3): 157 - 166. [Abstract] [PDF] |
||||
![]() |
M. C. Dalakas and S. A. Smith A "nema" of hope in the treatment of late-onset nemaline myopathy Neurology, August 12, 2008; 71(7): 472 - 473. [Full Text] [PDF] |
||||



